Effects of sigma agonist compounds on local cerebral glucose utilization: relationship to psychotomimetic properties.
The effects of 3, structurally unrelated sigma agonist compounds on local cerebral glucose utilization (LCGU) were compared. The common effects of sigma agonist compounds on LCGU included a moderate, global elevation of LCGU. Superimposed upon this elevation were larger increases in LCGU occurring mainly in components of the limbic system, and the pyramidal and extrapyramidal motor systems. The only structures whose metabolic rates were significantly elevated by all 3 compounds were the frontal cortex and the anterior cingulate cortex. The altered metabolic activity in these limbic brain regions may underly the psychotomimetic effects produced by sigma agonist compounds.
D000818:Animals; D001921:Brain / Q000378:metabolism*; D004148:Dioxolanes / Q000494:pharmacology*; D004149:Dioxoles / Q000494:pharmacology*; D005947:Glucose / Q000378:metabolism*; D006213:Hallucinogens / Q000494:pharmacology*; D008297:Male; D010620:Phenazocine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010622:Phencyclidine / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D004148:Dioxolanes; D004149:Dioxoles; D006213:Hallucinogens; D010880:Piperidines; C005840:dioxadrol; C012134:SK&F 10047; D005947:Glucose; D010620:Phenazocine; D010622:Phencyclidine